Detalhe da pesquisa
1.
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
Circulation
; 144(22): 1750-1759, 2021 11 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34706555
2.
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
Circulation
; 144(23): 1845-1855, 2021 12 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34710343
3.
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
Circulation
; 143(1): 33-44, 2021 01 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33148016
4.
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
N Engl J Med
; 380(1): 11-22, 2019 01 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30415628
5.
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
Circulation
; 141(5): 367-375, 2020 02 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31707829
6.
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies.
Eur Heart J Suppl
; 22(Suppl J): J34-J48, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-33061866
7.
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.
Eur Heart J
; 45(13): 1173-1176, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38252107
8.
Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
Prostaglandins Other Lipid Mediat
; 125: 57-64, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27418543
9.
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
J Am Coll Cardiol
; 83(16): 1529-1539, 2024 Apr 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38530686
10.
Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.
Eur Heart J Open
; 3(6): oead114, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-38035037
11.
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.
J Am Heart Assoc
; 12(5): e026756, 2023 03 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36802845
12.
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
J Am Coll Cardiol
; 79(17): 1660-1671, 2022 05 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35483753
13.
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
J Am Heart Assoc
; 11(6): e022937, 2022 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35261279
14.
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
J Am Coll Cardiol
; 78(15): 1525-1537, 2021 10 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34620410
15.
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
J Cardiovasc Pharmacol
; 54(3): 196-203, 2009 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-19597368
16.
Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.
Cardiol Ther
; 8(1): 79-90, 2019 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-30788718
17.
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
Am J Cardiol
; 124(5): 696-701, 2019 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31277790
18.
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
Postgrad Med
; 131(6): 390-396, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-31306043
19.
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
J Am Coll Cardiol
; 73(22): 2791-2802, 2019 06 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30898607
20.
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
J Womens Health (Larchmt)
; 27(9): 1170-1176, 2018 09.
Artigo
Inglês
| MEDLINE | ID: mdl-29583081